1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ethosuximide Syrup
Trade Name: Zarontin; Suxinutin
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anticonvulsant, anti-epileptic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

Germ Cell Mutagenicity: Category 2
Reproductive Toxicity: Category 1B

EU Classification:

EU Indication of danger: Toxic to reproduction, Category 2
Mutagenic: Category 3

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.

Label Elements

Signal Word: Danger
Hazard Statements:
H341 - Suspected of causing genetic defects
H360D - May damage the unborn child

Precautionary Statements:
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards
No data available


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethosuximide</td>
<td>77-67-8</td>
<td>201-048-7</td>
<td>Xn, R22; Repr. Cat.2, R61; Mut. Cat.3, R68</td>
<td>Acute Tox. 4, H302; Repr. 1B, H360D; Muta. 2, H341</td>
<td>5.0</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium saccharin</td>
<td>128-44-9</td>
<td>204-886-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Glycerin, USP</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium dihydrogen citrate</td>
<td>18996-35-5</td>
<td>242-734-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>FD &amp; C Red No. 40</td>
<td>25956-17-6</td>
<td>247-368-0</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>FD&amp;C yellow No.6 aluminum lake</td>
<td>15790-07-5</td>
<td>239-888-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>208-534-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Flavor</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Water, purified</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not flammable.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid contact with eyes. Avoid contact with skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product
## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

### Ethosuximide

Pfizer OEL TWA-8 Hr: 2 mg/m³

### Sucrose

<table>
<thead>
<tr>
<th>ACGIH Threshold Limit Value (TWA)</th>
<th>10 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>10.0 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>6 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>

### Glycerin, USP

<table>
<thead>
<tr>
<th>ACGIH Threshold Limit Value (TWA)</th>
<th>10 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td>20 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL -TWAs</td>
<td>50 mg/m³</td>
</tr>
</tbody>
</table>

### Exposure Controls

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Liquid</th>
<th>Color:</th>
<th>Red-orange</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solubility:</td>
<td>Soluble: Water</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ethosuximide
No data available

Citric acid, anhydrous
No data available

FD & C Red No. 40
No data available

FD&C yellow No.6 aluminum lake
No data available

Flavor
No data available

Glycerin, USP
No data available

Sodium saccharin
No data available

Sodium dihydrogen citrate
No data available

Sucrose
No data available

Sodium benzoate
No data available

Water, purified
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability: No data available

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.
10. STABILITY AND REACTIVITY

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May be harmful if swallowed. May cause eye irritation (based on components).

Known Clinical Effects: Effects reported during clinical use included vomiting and diarrhea. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Clinical use of this drug has caused decreased blood cell count, increased eosinophils in blood or tissue (eosinophilia), skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). May cause adverse effects on the developing fetus.

Acute Toxicity: (Species, Route, End Point, Dose)

Ethosuximide

Mouse Oral LD50 1530 mg/kg
Rat Oral LD50 1950mg/kg
Mouse Intravenous LD50 780mg/kg
Mouse Intravenous LD50 1070mg/kg

Citric acid, anhydrous

Rat Oral LD50 3000 mg/kg

Glycerin, USP

Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg
Rat Inhalation LC50 1hr > 570 mg/m³
Rat Dermal LD 50 > 21.9 g/kg

Sodium saccharin

Mouse Oral LD50 17.5 g/kg
Rat Oral LD50 14.2 - 17g/kg
Rat Intraperitoneal LD50 7100mg/kg

Sodium dihydrogen citrate

Rat IP LD50 1348 mg/kg
Mouse IV LD50 49mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Sodium benzoate
**11. TOXICOLOGICAL INFORMATION**

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**
- Citric acid, anhydrous
  - Eye Irritation: Rabbit, Severe
  - Skin Irritation: Rabbit, Mild

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Ethosuximide**
- 3 Month(s) Dog Oral 100 mg/kg/day LOAEL Liver
- 26 Week(s) Rat Oral 676 mg/kg/day NOAEL None identified
- 26 Week(s) Dog Oral 100 mg/kg/day NOAEL None identified
- 26 Week(s) Monkey Oral 200 mg/kg/day NOAEL None identified
- 1 Year(s) Mouse Oral 136 mg/kg/day LOAEL Liver

**Sodium saccharin**
- 36 Week(s) Rat Oral 756 g/kg LOAEL Kidney, Ureter, Bladder
- 54 Day(s) Rat Oral 32400 mg/kg LOAEL Immune system

**Sodium benzoate**
- 10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood
- 10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

**Ethosuximide**
- Embryo / Fetal Development Rat 60 mg/kg/day LOEL Teratogenic
- 2 Generation Reproductive Toxicity Rat Oral 0.2% LOAEL Not Teratogenic, Embryotoxicity
- Embryo / Fetal Development Mouse Oral 60 mg/kg/day LOAEL Teratogenic
- Prenatal & Postnatal Development Mouse Oral 50 mg/mL NOAEL Embryotoxicity, Reproductive toxicity, Developmental toxicity

**Sodium benzoate**
- Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity,

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Ethosuximide**
- In Vitro Cytogenetics Human Negative
- In Vivo Micronucleus Mouse Bone Marrow Positive

**Sucrose**
- Bacterial Mutagenicity (Ames) Salmonella Negative
11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Sodium saccharin
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
*Oncorhynchus mykiss* (Rainbow Trout)  
LD50 96 Hours 50 mg/L

*Daphnia magna* (Water Flea)  
EC50 24 Hours >500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Ethosuximide
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons:
EU EINECS/ELINCS List 201-048-7

Sodium dihydrogen citrate
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 242-734-6

Citric acid, anhydrous
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 201-069-1

FD & C Red No. 40
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 247-368-0

FD&C yellow No.6 aluminum lake
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 239-888-1

Sodium benzoate
CERCLA/SARA 313 Emission reporting Not Listed
### 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>208-534-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium saccharin</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>204-886-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavor</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>200-334-9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycerin, USP</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water, purified</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>231-791-2</td>
</tr>
</tbody>
</table>

Material Name: Ethosuximide Syrup

Revision date: 11-Apr-2015

Version: 3.0
16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Mutagenic: Category 3
Toxic to Reproduction: Category 2
Xn - Harmful

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risks of irreversible effects.

Data Sources: Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 12 - Ecological Information. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 11-Apr-2015

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet